Sign in

Trial result ·

Efficacy and safety of LEVI-04 in patients with osteoarthritis of the knee: a randomised, double-blind, placebo-controlled, phase 2 trial.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This study tested a new drug called LEVI-04 for knee osteoarthritis. It was a phase 2 trial, with people put into groups by chance. Neither people nor staff knew who got the real drug. There were 518 people with painful knee osteoarthritis seen on X-ray. They came from Poland, Denmark, Moldova, Hong Kong and the Czech Republic. Up to week 16, they got a monthly drip into a vein. Some got a dummy drug. Others got LEVI-04 at 0·3, 1·0 or 2·0 mg/kg. Safety was checked up to week 30.

What they found

At week 17, each LEVI-04 group had less knee pain than the dummy group. The largest drop in pain was seen with the 2·0 mg/kg dose. Serious side effects were not more common with LEVI-04. Other side effects were not more common either. There was no rise in joint problems, such as fast-worsening osteoarthritis.

What it means for patients

The authors say LEVI-04 was well tolerated. They say it eased pain and helped the knee work better. They think adding to the body's own p75NTR may help treat osteoarthritis.

Why it is not certain yet

This was a phase 2 trial, which is a mid-stage test. Treatment ran up to week 16, and safety checks ran to week 30. The abstract does not give results beyond week 30. It also gives no figures on how well the knee worked. Mid-stage trials like this one need larger trials to confirm them. The study was funded by Levicept.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Efficacy and safety of LEVI-04 in patients with osteoarthritis of the knee: a randomised, double-blind, placebo-controlled, phase 2 trial.

PubMed · PMID 41905364

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Osteoarthritis publications
Efficacy and safety of LEVI-04 in patients with osteoarthritis of the knee: a randomised, double-blind, placebo-controlled, phase 2 trial. · Osteoarthritis news explained – Frontlight Research